NRGene Technologies 2025: The numbers jumped, now commercialization has to prove itself

Getting To Know The Company

NRGene is no longer just a small genomic software company selling cloud-based analysis. In 2025 it tried to turn itself into a commercialization company built around intellectual property, breeding traits, and agri products, mainly through black soldier fly, licensing deals, and internally developed assets. That is the core shift. The company will no longer be judged mainly on how many customers use its software, but on whether it can hold valuable genetics long enough to turn them into royalties, product sales, and cash.

What clearly worked this year? Revenue jumped to $3.17 million, gross profit rose to $1.92 million, cash flow from operations turned positive at $855 thousand, and cash climbed to $4.139 million. At the same time, the black soldier fly project moved from a technical story to a first commercial agreement, and after year-end the company also started initial commercial sales of MaxBites in Canada.

What is easy to misread on first glance? Most of the jump did not come from a broad commercial engine. It came from IP monetization, especially the Above Food transaction. Out of $3.17 million of 2025 revenue, $2.227 million came from the sale and commercialization of royalty-bearing development assets. End-product sales were only $45 thousand. Meanwhile, cloud revenue fell to $160 thousand, active customers in the software and services model fell from 6 to 3, and the company ended the year with no cloud backlog at all.

That makes 2025 a bridge year, not a clean breakout year. An old engine is shrinking, while the new engine still has to prove pace. The 2026 read boils down to two questions: can black soldier fly move from pilots into repeat orders, and can NRGene close the gap between revenue that was recognized in the statements and cash engines that actually repeat. The actionability filter matters too: market cap is only about NIS 33.6 million, and turnover on the latest trading day was roughly NIS 21 thousand. This is a very small and illiquid stock, so any commercial or financing update can move the read quickly.

Formally, the company reports one segment. Economically, there are four very different engines:

One more point belongs at the top of the article, not at the bottom. The BSF engine sits inside NRGene Canada, and after the $1.6 million financing in 2025 the listed company's ownership dropped to about 83%. So even if that business creates material value, not all of it will flow one-for-one to common shareholders of the public company. That does not kill the upside, but it does change how upside should be read.

Events And Triggers

This report moved because of three events, not one. The Above Food transaction lifted the numbers, black soldier fly started to move from lab work into commercialization, and the legacy software and services layer kept shrinking, partly by choice and partly because of pressure.

Above Food lifted the year, but did not clean it up

The Above Food transaction is the main reason the statements look different. In 2025 the company recognized $2.168 million of revenue from the deal and ended the year with $2.247 million of backlog tied to the sale of IP assets. That is what drove the top line and the gross profit line.

But this is not clean revenue. At the end of 2025 the company also held $1.16 million of marketable securities, shares received as part of the transaction. On the other side of the balance sheet it carried $1.98 million of deferred revenue for the clubroot-resistant canola project that had not yet been transferred, plus a $1.069 million liability for excess consideration created by the sale of Above Food shares. In other words, part of the monetization has already gone through the income statement, but not all of the value has yet turned into simple, unrestricted cash.

The March 2026 presentation shows the story moved forward after the balance sheet date. The company says it had by then received about $4.5 million in cash and share-sale proceeds for the assets sold, that only 57 thousand shares remained, and that excess consideration had already reached $1.4 million. But here too the fine print matters: 80% of that excess is supposed to go back to Above Food, and only 20% stays with NRGene. So not every dollar entering through this deal is really kept by the listed company.

BSF moved from build-out into proof mode

If Above Food lifted 2025 in the statements, black soldier fly is what will decide whether 2026 looks like another bridge year or the start of a real commercial engine. In January 2025 NRGene Canada raised $1.6 million to support commercialization. In August 2025 the company signed its first commercial agreement to sell customer-tailored larvae in North America. During February 2026 it started first commercial sales of dried BSF larvae under the MaxBites brand.

The key link is capacity. The company completed an egg and larvae production facility in January 2025 with capacity of 6.5 million eggs per day, and is also setting up a second facility in Alberta, 20 times larger than the existing one, with targeted start-up during April 2026. As long as this remained a demo story, the thesis was mostly technical. Once there is a facility, a first commercial contract, customer comparisons, and initial retail sales, the thesis becomes operational. That is a very different test, and it is now the active bottleneck.

The legacy engine weakened faster

The sacrifice behind this report is visible. Revenue from cloud access fell 54% to $160 thousand. Revenue from genomic analysis and production services slipped to $738 thousand. The number of active customers in that model fell from 6 to just 3, and the company explicitly says competition in genetic testing is eroding profitability, while some customers have become more reluctant to buy services from Israeli companies. At the same time, total signed engagements in genetic testing fell to about $0.2 million in 2025, down from about $0.9 million in 2024.

That matters because the company is not only moving to new engines. It is also losing its old cushion. The market should ask not only whether BSF can work, but how quickly it needs to work in order to replace what is already fading.

Efficiency, Profitability And Competition

The profitability improvement is real, but it did not come from the place investors would want to trust over time. Gross profit rose from $267 thousand to $1.92 million, and adjusted gross margin rose from 34% to 70%. On the surface, that looks like a sharp turn. In quality terms, it is more complicated.

First, almost all of the improvement came from revenue recognition tied to the sale of developed IP assets, while much of the underlying development cost had already been expensed in prior years. That is one reason why the second half of 2025 looks like a different business, with $2.538 million of revenue and $320 thousand of operating profit, after a weak first half that still showed a $1.898 million operating loss.

Second, the company did not improve profitability only through mix. It also got leaner. R&D expense fell 26% to $1.341 million, sales and marketing expense fell 63% to $347 thousand, and G&A fell 8.5% to $1.802 million. Headcount fell from 29 to 23. That is not just efficiency. It is also a sign that the company is concentrating its cash on a narrower set of bets.

This is where a yellow flag belongs. When a company shows a big improvement in operating loss, the right question is whether it built a stronger engine or simply shortened the road to the next reporting period. At NRGene the answer is both, but the weight still leans more toward cost reduction and accounting recognition than toward scaled end-market product sales.

Another quality issue is concentration. In 2025 the company had 3 principal customers that together accounted for $2.814 million, roughly 89% of total revenue. Geographically, $2.88 million, about 91% of revenue, came from North America. That is not automatically a problem when one year is shaped by a large monetization event and first commercial traction in one region. It is a problem if the numbers are read as though the company already has a wide and diversified commercial base.

On competition, the most interesting layer is outside BSF. In genetic testing the company itself describes margin erosion and stronger competition, and that also shows up in the numbers. So part of the improvement in 2025 came from moving away from a more commoditized service lane and toward a lane built around owned IP and potential royalty streams. Strategically that makes sense. It also raises execution risk, because now any delay in commercialization hits the heart of the thesis.

There is one more point the market can easily miss. The BSF engine sits, as noted, in a subsidiary where ownership fell to about 83%. So even if NRGene Canada starts showing sharp operating progress, part of the value already belongs to minority holders. That is a meaningful difference between "the asset is working" and "all of the value belongs to public shareholders."

Cash Flow, Liabilities And Capital Structure

The good news is that the immediate pressure came down. The less good news is that this still does not read like a self-funding business.

Cash and cash equivalents rose to $4.139 million at the end of 2025, from $1.289 million a year earlier. Working capital rose to $1.163 million, from $221 thousand. Cash flow from operations also turned positive at $855 thousand, after negative $3.564 million in 2024. Anyone stopping at those three lines could conclude the cash problem is behind the company. That would be too early.

To read the cash flow correctly, the cash bridge has to be defined. In all-in cash flexibility terms, meaning after actual cash uses, the company still does not look like a quiet cash generator. Operating cash flow was helped by a $1.828 million increase in deferred revenue and a $1.361 million increase in other payables and accrued expenses. At the same time, the group still spent $663 thousand on capitalized development and paid $231 thousand in lease liabilities. The picture improved a lot, but a meaningful part of the improvement still sits on timing, a one-off transaction, and external support rather than on deep recurring cash generation.

The balance sheet tells the same story. On one side, cash rose and equity increased to $4.419 million. On the other side, current liabilities jumped to $5.064 million, mainly because deferred revenue climbed to $2.396 million and other payables and accrued liabilities climbed to $2.441 million. Inside the latter sits the $1.069 million excess-consideration liability tied to the Above Food mechanics. This is not classic bank debt, but it is a reminder that not all of the cash improvement belongs to the company in a clean way.

In debt terms, there is no classic maturity wall here. The company has no material financial debt burden, and lease liabilities stood at $130 thousand current and $51 thousand non-current. That helps. But dependence on external funding did not disappear. Management explicitly says the company continues to rely on operating activity, government grants, partnerships, subsidiary-level investors, and additional raises if needed.

The strongest signal on this point does not sit only in the tables. It also sits in behavior. During 2025 the compensation mix of employees and officers was shifted more heavily toward options and restricted shares. The chairman and CEO gave up 50% of their monthly cash compensation from March through December 2025 in exchange for options, and the structure continued into 2026. That is responsible cash management. It is also a clear sign that management is still acting like every dollar matters.

Another external warning signal is the auditors' emphasis-of-matter reference to note 1(a), highlighting ongoing losses and management's expectation that losses will continue, even though management also states that available funding sources should support activity for at least 12 months from the date the statements were approved. This is not a going-concern collapse. It is also not an all-clear.

Outlook

Before going into detail, four points should sit in front of the reader when thinking about 2026:

• This is a proof year for BSF, not another software year. If BSF does not start producing repeat orders, it is hard to see what replaces the Above Food lift.
• Most of the Above Food accounting boost is already behind us. From here the question is cash quality, not just reported revenue.
• Canola and Supree still look more like option value than base value. Both matter, but neither one carries the statements today.
• The company is smaller and more concentrated now. That can help efficiency, but it also means fewer cushions if one engine slips.

What has to happen in BSF

The first trigger is operational. The new Alberta egg facility is supposed to start operating during April 2026. That is critical because the company will no longer be judged mainly on breeding quality, but on whether it can actually produce eggs, larvae, and finished products at a commercial rate.

The second trigger is commercial. By the end of 2025 the company had one first commercial BSF agreement, alongside comparison trials with 3 potential customers. As long as those remain isolated, this is still a proof-of-concept story. The moment a second and third customer arrive, the read changes quickly.

The third trigger is business-model quality. The company is not trying to enter the market just as another insect protein producer. It is trying to sell genetics upstream and premium branded products like MaxBites and MaxFrass downstream. That is potentially more attractive, but also more complex. It requires partner farmers, production, branding, channel execution, and pricing that supports the entire structure.

In the March 2026 presentation management shows a 2027 BSF revenue expectation of $6.8 million. That is a very ambitious number relative to the non-material BSF sales of 2025. So 2026 should be read as a proof year, not a harvest year. If the facility starts on time, sales repeat, and agreements move from pilot into orders, the market will start reading NRGene differently. If not, that framework will look premature.

What can come from canola, and what is still missing

The clubroot-resistant canola project is one of the most interesting assets in the portfolio precisely because it already showed field proof. In August 2025 the developed lines showed near-full resistance, with fewer than one diseased plant per 500 plants tested, versus 73% to 85% disease incidence in control varieties. That is a strong technical result.

But the missing piece is the contract. As of the report date, discussions with leading seed companies had not yet matured into licensing agreements. So canola today is an asset with biological proof and commercial potential, but not yet with a signed recurring-revenue agreement. Until there is a first contract, it should be read as option value rather than as a funded engine.

The same is true for the other seed projects. In the cherry tomato project with Top Seeds, the company says the variety testing phase was extended with target customers, pushing the first expected royalty revenue to 2027. That is not a cancellation. It is another example of how long the time gap still is between technical progress and revenue recognition in NRGene's model.

Supree is optionality, but still small and messy

Supree generated $46 thousand of tomato sales in 2025, versus $21 thousand in 2024. That is growth, but still nowhere near a scale that changes the group profile. The more interesting layer comes after the balance sheet date: in January 2026 Supree signed a settlement with Tzabar-Tek under which it will pay NIS 970 thousand over 12 months, while the company also tries to shift to a new model based on open-field production and other strategic partners. In the March 2026 presentation it also points to a first pilot with a customer in Japan.

So the implication is double-sided. There may be a real product category here. But here too, 2026 is about model transition and commercialization proof, not about an engine that already carries the numbers.

Risks

The central risk is conversion risk. NRGene knows how to create projects, traits, partnerships, and technological proof. The open question is how quickly all of that turns into repeatable revenue. This is not a generic comment. It is the main business risk.

The second risk is concentration. Three customers accounted for almost 89% of revenue, and North America accounted for about 91% of sales. That raises sensitivity to any delay at one customer, any change at one partner, and any execution issue in the Canadian operating chain.

The third risk is continued dependence on external funding even in a stronger-looking year. The company makes it clear that it still relies on grants, partnerships, subsidiary-level investors, and possible raises when needed. The report is stronger, but the model does not yet finance all of its growth internally.

The fourth risk is FX. Most revenue is in U.S. dollars, while a large share of costs is in shekels and Canadian dollars. The company does not hedge. In 2025 the finance line benefited from positive FX effects, but that can reverse.

The fifth risk is execution risk inside a partnership-heavy model. In BSF the company depends on partner farmers, a strategic investor for the new factory, and an ecosystem build-out. The memorandum for the new factory explicitly says either party may cancel if legal or regulatory issues arise before a binding agreement is signed. That means the most promising 2026 move is still not completely locked.

Finally, there is a simple market risk that still matters. The stock is very illiquid. Even if the thesis improves, not every investor will be able to act on it easily. If the thesis weakens, the exit can be sharp.

Conclusions

NRGene entered 2026 in a better position than the one in which it ended 2024. There is more cash, a smaller loss, better gross economics, and more commercial milestones that can now be measured. That is the supportive side of the thesis. The other side is that the improvement still depends heavily on IP monetization and one complex transaction, while the new product engine is only at the start of its proof stage.

Current thesis: NRGene has moved beyond the question of whether it has strong technology and into the question of whether it can commercialize that technology again and again.

What has changed versus the older read of the company? The main question is no longer whether it can sell genomic analysis or sign interesting collaborations. The question is whether BSF, canola, and Supree can build a recurring revenue layer quickly enough while the older services base is shrinking.

Counter-thesis: It is possible that 2025 was already the real turning point, and that in a company this small, even a few mid-sized contracts, one facility starting on time, and one more license agreement are enough to change the profile of the statements much faster than it seems today.

What can change the market's reading over the short to medium term? Mainly three things: orderly start-up of the new egg facility during April 2026, repeat BSF sales after the first commercial sale, and proof that the continuing monetization of Above Food creates higher-quality cash rather than more accounting noise.

Why does this matter? Because if NRGene clears this conversion stage, it can stop looking like a small agtech company with interesting technology but thin revenue, and start looking like an IP platform with at least one real commercial engine.

Over the next 2 to 4 quarters, the thesis strengthens if BSF shows repeat customers, production capacity coming online on time, and one or two additional commercial agreements. It weakens if, after the Above Food lift, the company goes back to relying mainly on future option value without measurable commercial pace.